This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Boston Scientific (BSX) Q4 Earnings Miss, Operating Margin Up
by Zacks Equity Research
Boston Scientific's (BSX) organic revenues at each of its core business segments and geographies increase in the fourth quarter of 2022.
Henry Schein (HSIC) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Henry Schein's (HSIC) dental business is likely to have gained in Q4 from the acquisition of Midway Dental.
Thermo Fisher (TMO) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Robust year-over-year growth in the Analytical Instruments and the Laboratory Products and Biopharma Services segments boost Thermo Fisher's (TMO) Q4 revenues.
Edwards Lifesciences (EW) Q4 Earnings Top, Margins Increase
by Zacks Equity Research
Edwards Lifesciences (EW) continues to register strong momentum in TMTT, led by the continued adoption of the PASCAL platform in Europe.
Stryker's (SYK) Q4 Earnings Beat Estimates, Volume Improves
by Zacks Equity Research
Stryker's (SYK) fourth-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurts sales growth and rising costs adversely impact margins.
5 Top Dividend Growth Stocks to Buy in the Month of Love
by Sweta Killa
Archer-Daniels (ADM), Agilent Technologies (A), Republic Services (RSG), Deere & Company (DE) and Cardinal Health (CAH) seem solid picks for this month.
LabCorp (LH) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Ongoing sales rebound in the base business for the Diagnostics and Drug Development segments likely drive LabCorp (LH) Q4 revenues.
Integer Holdings (ITGR) Announces Solid Preliminary Q4 Revenues
by Zacks Equity Research
Integer Holdings' (ITGR) revenue growth in the fourth quarter is likely to have been boosted by continued strong customer demand for its products.
Baxter (BAX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Baxter's (BAX) fourth-quarter results are likely to reflect growth in elective surgical procedures, offset by currency and supply challenges. Hillrom's products are likely to have boosted sales.
Here's Why You Should Retain Nevro (NVRO) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Nevro (NVRO), owing to its R&D edge.
BD (BDX) Gears Up for Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have driven up Q1 sales.
Bio-Rad (BIO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Sustained sales gains in terms of the Bio-Rads (BIO) process media, western blotting, Droplet Digital PCR and qPCR products are likely to drive Q4 revenues.
Charles River (CRL) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
The broad-based demand and meaningful price increases in the RMS business particularly in North America are expected to have contributed to Charles River's (CRL) top line in Q4.
Cardinal Health (CAH) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) second-quarter fiscal 2023 results are likely to reflect solid performance in the Pharmaceutical segment. However, inflation and supply chain constraints are likely to have continued.
ResMed's (RMD) Q2 Earnings Beat Estimates, Margins Falls
by Zacks Equity Research
ResMed's (RMD) mask sales growth was strong across the globe, reflecting a post-COVID pandemic awareness about the importance and need for respiratory hygiene and respiratory health.
Is Cardinal Health (CAH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Cardinal Health (CAH) and COMPASS Pathways PLC Sponsored ADR (CMPS) have performed compared to their sector so far this year.
McKesson (MCK) to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
McKesson's (MCK) fiscal third-quarter results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
AmerisourceBergen (ABC) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal first-quarter results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.
What's in the Cards for Illumina (ILMN) in Q4 Earnings?
by Zacks Equity Research
Negative foreign exchange impact and consumables inventory deleveraging are expected to have affected Illumina's (ILMN) top line during the fourth quarter.
CVS Health (CVS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
CVS Health's (CVS) digital capabilities are expected to have driven consumer engagement across all CVS Health businesses in Q4.
Cardinal Health (CAH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Cardinal (CAH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should Value Investors Buy Cardinal Health (CAH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
STERIS (STE) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
STERIS' (STE) hospital capital spending is expected to have remained robust in Q3, as evident from the healthcare backlog's recent trend.
Zimmer Biomet (ZBH) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet (ZBH) is expected to have witnessed continued recovery in its legacy business in the fourth quarter, despite the choppy market situation.